Pulse Biosciences Management
Management criteria checks 2/4
Pulse Biosciences' CEO is Kevin Danahy, appointed in Sep 2022, has a tenure of 1.67 years. total yearly compensation is $5.86M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.065% of the company’s shares, worth $272.73K. The average tenure of the management team and the board of directors is 2.2 years and 6.5 years respectively.
Key information
Kevin Danahy
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 7.4% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2.2yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Dec 16
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$433k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$39m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$2m | US$350k | -US$59m |
Compensation vs Market: Kevin's total compensation ($USD5.86M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
CEO
Kevin Danahy (52 yo)
1.7yrs
Tenure
US$5,864,450
Compensation
Mr. Kevin P. Danahy is Chief Executive Officer of Pulse Biosciences, Inc. from September 2022 and serves as its President from October 2023 and was its President from September 2022 until 2023. He served a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.5yrs | US$257.41k | 67.86% $ 284.8m | |
| President & CEO | 1.7yrs | US$5.86m | 0.065% $ 272.7k | |
| CTO & Director | 1.7yrs | US$5.39m | 0.27% $ 1.2m | |
| Chief Strategy Officer | 2.8yrs | US$1.69m | 0.18% $ 761.7k | |
| Chief Science Officer | 9.5yrs | no data | no data | |
| General Counsel & Corporate Secretary | 3yrs | no data | no data | |
| Vice President of Human Resources | 4.3yrs | no data | no data | |
| Senior Vice President of Engineering | 2.7yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Chief Science Officer of Cardiac Surgery | less than a year | no data | no data |
2.2yrs
Average Tenure
57yo
Average Age
Experienced Management: PLSE's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.5yrs | US$257.41k | 67.86% $ 284.8m | |
| CTO & Director | 8.7yrs | US$5.39m | 0.27% $ 1.2m | |
| Independent Director | 3.8yrs | US$208.89k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$123.47k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$173.00k | 1.36% $ 5.7m | |
| Lead Independent Director | 6.5yrs | US$180.07k | 0% $ 0 |
6.5yrs
Average Tenure
57yo
Average Age
Experienced Board: PLSE's board of directors are considered experienced (6.5 years average tenure).